Mapmygenome & Apollo Clinic Partner to Launch DNA-Based Immunity Testing

MapmyGenome & Apollo Clinic Partner to Launch DNA-Based Immunity Testing

MapmyGenome, a genomics company offering personalised health solutions based on genetic tests, has joined hands with Apollo Clinic to offer DNA-based tests that give risk and immunity reports. These tests include screening for health & wellness and ancestry testing during the Covid-19 pandemic — for understanding genetic predispositions of people to know why some people suffer more than others.

The Science Behind the Partnership

Researchers across the globe have been studying the viral genome to understand its mechanism of action and to find possible ways to stop the spread. Genomics has proven to be a valuable tool in COVID diagnostics and testing. COVID-19 treatment can be personalised with genetic screening, by testing for biomarkers which affect drug response for efficacy and toxicity.

“Our own team has researched 4,000 Indian samples to estimate DNA-based COVID risk and severity in Indian patients. Research has shown that genes involved in cytokine production, regulation, and immune response are linked with cytokine storm, or a severe immune reaction in COVID patients. Screening for these genetic markers could help identify risk for cytokine storm, infectiousness, and thereby, severe COVID-19 outcomes,” said Anu Acharya, CEO, MapmyGenome.

Tests Available Through Apollo Clinic

• Genomepatri — a master health test with 100+ reports on lifestyle disease, physiological traits, drug response, and carrier status

• Genomepatri Lite — focused on cardiology and oncology, with 50 reports on heart health, metabolic traits, cancer risk, and drug response

• Genomepatri Heritage — the first DNA ancestry test offering ethnicity mapping for the Indian population